Immunotherapy plus chemo shows promise for esophageal cancer before surgery
NCT ID NCT07437898
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether giving the immunotherapy drug adebrelimab along with standard chemotherapy before surgery can help people with locally advanced esophageal cancer. About 42 participants will receive the treatment every 3 weeks, then have surgery. The main goal is to see how many patients have no cancer cells left in the removed tissue (pathological complete response).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
adebrelimab (an immunotherapy drug) plus chemotherapy (nab-paclitaxel and cisplatin)
What this could lead to
If successful, this combination could become a standard pre-surgery treatment to shrink tumors and improve survival for esophageal cancer patients.
What could go wrong
This is a small, early-phase trial with only 42 participants, so results may not apply broadly. Side effects from immunotherapy and chemotherapy can be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Affiliated Hospital of Putian University
RECRUITINGPutian, Fujian, 351100, China